Cambridge-based Glympse Bio has closed an oversubscribed $46.7 million Series B financing. The proceeds from the financing will support continued development of Glympse’s novel biosensor platform in fibrotic diseases such as Non-Alcoholic Steatohepatitis (NASH), oncology, and infectious diseases. NASH is a disease that impacts 16 million people in the U.S. and 100 million worldwide. The […]

Waltham-based Adagio Therapeutics has launched with the closing of a $50 million Series A financing to advance its portfolio of coronavirus antibodies as both therapeutics and prophylactics against SARS-CoV-2 as well as future coronavirus outbreaks. Adagio’s antibody candidates have been uniquely engineered and optimized to provide broad protection against SARS-CoV-2, SARSCoV-1, and additional circulating bat […]

Cambridge-based Relay Therapeutics has announced an initial public offering of 20,000,000 shares of its common stock at a price to the public of $20.00 per share. The gross proceeds of the offering are expected to be $400 million. In addition, the underwriters have a 30-day option to purchase up to 3,000,000 additional shares of common […]

New information on the industry response to the pandemic is arriving at a fast and furious pace. The following links are provided to help you keep up to date:   Moderna Completes Enrollment of Phase 2 Study of its mRNA Vaccine; Phase 3 to Begin in Late July  https://investors.modernatx.com/news-releases/news-release-details/moderna-completes-enrollment-phase-2-study-its-mrna-vaccine   Moderna and ROVI Announce Collaboration […]

Blueprint Medicines, a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, has entered into a global collaboration with Roche and Genentech, a member of the Roche Group, to develop and commercialize pralsetinib, an investigational precision therapy for the treatment of people with cancer driven by oncogenic RET alterations, including non-small […]

Kymera Therapeutics has entered into a strategic collaboration with Sanofi to develop and commercialize first-in-class protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases. The companies will also partner on a second earlier stage program. Kymera will receive $150 million in cash upfront and may receive more than $2 billion in potential development, regulatory and sales milestones, as […]

Pfizer has pledged $100 million to the newly launched Antimicrobial Resistance (AMR) Action Fund to help address the significant global public health need for new antibiotics due to the rapid rise of antibiotic-resistant infections. The AMR Action Fund is a ground-breaking collaboration among more than 20 biopharmaceutical companies that aims to bring 2-4 new antibiotics […]

Translate Bio, a Lexington-based, clinical-stage mRNA therapeutics company, and Sanofi Pasteur, the vaccines global business unit of Sanofi, have agreed to expand their existing 2018 collaboration and license agreement to develop mRNA vaccines for infectious diseases. The expansion of this agreement will further unite Translate Bio’s expertise and knowledge from more than 10 years of […]

Vaccines work by mimicking disease agents to stimulate the immune system, building up a defense mechanism that remains active in the body to fight future infections. mRNA vaccines offer an innovative approach by delivering a nucleotide sequence encoding the antigen or antigens selected for their high potential to induce a protective immune response. mRNA vaccines […]

Boston-based biotech Akouos has raised gross proceeds of $244 million in its June stock market debut. Akouos is a precision genetic medicine company dedicated to developing gene therapies for people worldwide who live with disabling hearing loss. Leveraging its precision genetic medicine platform that incorporates a proprietary adeno-associated viral (AAV) vector library and a novel delivery […]